224 related articles for article (PubMed ID: 38685841)
81. Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors.
Sheng-Tanner X; McKerlie C; Spaner D
Transplantation; 2000 Dec; 70(12):1683-93. PubMed ID: 11152097
[TBL] [Abstract][Full Text] [Related]
82. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
Nguyen H; Alawieh A; Bastian D; Kuril S; Dai M; Daenthanasanmak A; Zhang M; Iamsawat S; Schutt SD; Wu Y; Sleiman MM; Shetty A; Atkinson C; Sun S; Varela JC; Tomlinson S; Yu XZ
Clin Cancer Res; 2020 Jul; 26(13):3481-3490. PubMed ID: 31919135
[TBL] [Abstract][Full Text] [Related]
83. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).
Choe H; Ferrara JLM
Expert Opin Ther Targets; 2021 Sep; 25(9):761-771. PubMed ID: 34669521
[TBL] [Abstract][Full Text] [Related]
84. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
85. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
86. Graft-Versus-Host Disease Following Liver Transplantation: Development of a High-Incidence Rat Model and a Selective Prevention Method.
Yu E; Ueta H; Kimura H; Kitazawa Y; Sawanobori Y; Matsuno K
Am J Transplant; 2017 Apr; 17(4):979-991. PubMed ID: 27732765
[TBL] [Abstract][Full Text] [Related]
87. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
Hashimoto D; Merad M
Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
[TBL] [Abstract][Full Text] [Related]
88. Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease.
Pérol L; Martin GH; Maury S; Cohen JL; Piaggio E
Immunol Lett; 2014 Dec; 162(2 Pt B):173-84. PubMed ID: 25445496
[TBL] [Abstract][Full Text] [Related]
89. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
90. Acute Graft-
Vinnakota JM; Zeiser R
Front Immunol; 2021; 12():748019. PubMed ID: 34691059
[TBL] [Abstract][Full Text] [Related]
91. Graft-versus-leukemia effect and its clinical implications.
Imamura M; Hashino S; Tanaka J
Leuk Lymphoma; 1996 Nov; 23(5-6):477-92. PubMed ID: 9031079
[TBL] [Abstract][Full Text] [Related]
92. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
93. Shared biology of GVHD and GVT effects: potential methods of separation.
Fowler DH
Crit Rev Oncol Hematol; 2006 Mar; 57(3):225-44. PubMed ID: 16207532
[TBL] [Abstract][Full Text] [Related]
94. Novel immunosuppression compounds and experimental therapies for chronic graft-versus-host disease.
Michael M; Shimoni A; Nagler A
Acta Haematol; 2013; 130(1):34-43. PubMed ID: 23392110
[TBL] [Abstract][Full Text] [Related]
95. Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.
Kornblau SM; Aycox PG; Stephens C; McCue LD; Champlin RE; Marini FC
Exp Hematol; 2007 May; 35(5):842-53. PubMed ID: 17577932
[TBL] [Abstract][Full Text] [Related]
96. Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies.
Naserian S; Leclerc M; Shamdani S; Uzan G
Front Immunol; 2020; 11():607030. PubMed ID: 33391276
[TBL] [Abstract][Full Text] [Related]
97. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
98. Advances in the understanding of acute graft-versus-host disease.
Morris ES; Hill GR
Br J Haematol; 2007 Apr; 137(1):3-19. PubMed ID: 17359368
[TBL] [Abstract][Full Text] [Related]
99. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.
Wang H; Yang YG
Immunol Rev; 2014 Mar; 258(1):30-44. PubMed ID: 24517424
[TBL] [Abstract][Full Text] [Related]
100. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]